Summary Fifty-one patients with advanced non-small cell lung carcinoma were treated with a combination of mitomycin C, vinblastine and cis-platin (MVP). Most 
Chemotherapy has a limited activity in non-small cell lung carcinoma (NSCLC); single agents achieve around 20% response rate, whilst combination chemotherapy containing cis-platin (DDP) may obtain up to 60% response rate (Sculier & Klastersky, 1984; Bakowski & Crouch, 1983) . Although multiple drug regimens seem to obtain higher response rates than single agents, their toxicity is often remarkable, especially when DDP is one of the drugs (Ruckdeschel et al., 1986) ; moreover, complete remission rate still remains below 10% even with the most aggressive regimens, and, finally, no survival advantage has so far been demonstrated in comparison with a no-treatment arm (Woods et al., 1985) . Thereby, chemotherapy should still be regarded as investigational and not routine treatment in NSCLC. The best known and frequently employed regimens in NSCLC contain DDP with either a vinca alkaloid (vindesine or vinblastine) or etoposide (VP16 213) (Ruckdeschel et al., 1986; Gralla et al., 1981; Longeval & Klastersky, 1982) . Mitomycin C has shown efficacy in the treatment of NSCLC, with a response rate of about 20% (Bakowski & Crouch, 1983; Samson et al., 1979) .
In the attempt to increase response rate and eventually improve survival, we treated patients with NSCLC with an aggressive combination of high-dose DDP, vinblastine and mitomycin C.
Materials and methods
Fifty-one patients with histologically or cytologically documented advanced NSCLC were entered in the study from September 1984 to June 1986 (Table I) Chest X-ray and imaging of marker lesions were performed before commencement of chemotherapy and before every cycle of DDP together with standard biochemical analysis of the blood. Haematological counts were repeated before every drug administration.
Response criteria and toxicity grading were those recommended by the WHO (1979) . Response duration and survival time were computed from the start of treatment. Actuarial survival was estimated by the method of Kaplan & Meier (1958) , and differences between survival curves were computed by the log-rank test (Mantel, 1966 The main toxicity has been marrow toxicity (Table III) (Figure 1 ). Table IV shows median survival times in relation to major prognostic factors. 0  1  2  3  4  6  8 10 12 14 16 18 20 22 24 26 28 30 MMC=mitomycin C l0mgm-2; VBL=vinblastine 5mgm-2; DDP=cis-platin lOOmgm-2.
Overall survival (N=51)
Time (days) Figure 1 Overall survival curve A significant difference in survival was apparent between patients with limited and extensive disease (P <0.025). Performance status was an important prognostic factor: patients with PS 0 or 1 survived significantly longer than those with PS 2 or 3 (P<0.001).
Prior exposure to chemotherapy also influenced survival, though the number of pretreated patients is small (P<0.01). Also, response to treatment was an important prognostic factor: Responding patients survived a median of 351 days in comparison to those who had NC or PD (223 days; P < 0.025). The difference was even more striking when responders were compared to progressing patients (MST 351 vs. 151 days; P <0.001). No significant difference existed in survival between responders and NC (P>0.1). Although the survival advantage of responders over non-responders does not mean that responsive patients survived longer because of the treatment, patients who responded to chemotherapy might represent a category of people who, for other reasons have a longer survival.
Eight patients have survived more than one year, and among these 5 had responded, 2 had NC and one was not evaluable for response (response rate 71%).
Weight loss in the last 3 months did not apparently influence survival (P>0.1).
Discussion
The most frequently used and effective combinations in NSCLC contain DDP and a vinca alkaloid (either vindesine or vinblastine) or VP16.313.
The addition of a third drug to these regimens has been attempted by several investigators with the aim of increasing response rate and possibly survival. Mitomycin C is known as one of the active agents in NSCLC (Bakowski & Crouch, 1983; Samson et al., 1979) ; its addition to the DDPvindesine regimen significantly increased the response rate from 27% to 54% in the preliminary report by Gralla et al. (1986) on 120 patients.
On the other hand, a 23-59% response rate has been reported by several authors, with vindesine and mitomycin alone (Luedke et al., 1986; Main et al., 1986; Sculier et al., 1986) .
However, the overall advantage of a three drug regimen over a two drug conbination has still to be demonstrated, especially if we consider the higher toxicity caused by addition of a third drug (namely DDP). The large ECOG trial comparing the four most active regimens for metastatic NSCLC (CAMP, DDP-vindesine, DDP-VP16.213, MVP), failed to demonstrate an advantage in survival of any arm over the others; nevertheless, the MVP schedule, which employed a lower DDP dose than ours (40 mg m 2) obtained a response rate (31%) which was significantly higher than that of the other regimens in patients with squamous carcinoma and adenocarcinoma. Overall, toxicity was noticeable in all DDP-containing regimens, but in particular nephrotoxicity was more frequent and severe in the DDP-vindesine arm (Ruckdeschel et al., 1986) .
In our study the addition of mitomycin C to DDP and vinblastine has apparently improved our previous experience in treating advanced NSCLC, over a DDP-VP16.213 combination in a similar group of patients (Giaccone et al., 1984) , although the comparison is not randomized.
The 50% response rate obtained in our trial with MVP is similar to that reported by other groups (Schulman et al., 1983; Mason & Catalano, 1980 ); although we obtained only one complete remission.
Emesis was as frequent and intense as we expected, despite prophylactic antiemetic treatment; neurotoxicity became a problem in a significant proportion of treated patients; in fact, 6 and 7 patients had moderate to severe peripheral neurotoxicity and constipation, respectively. Myelotoxicity has been universal, but an appropriate dose modification schedule applied to vinblastine administration and a reduction of intensity of chemotherapy after the two initial 4-weekly courses contained the life-threatening episodes; nevertheless one patient eventually died from sepsis while severely leukopaenic during the first cycle.
Our study confirmed performance status, disease extent and prior chemotherapy exposure as prognostic factors in NSCLC. In conclusion, the MVP combination is active in NSCLC, although the complete response rate is still unsatisfactory in the treatment of this disease. A careful evaluation of aggressive therapies like MVP has to be performed; further studies are warranted, especially in combined modality trials, as in a neoadjuvant setting, in borderline operable patients. 
